Oncology Precision Medicine Market Revenue to Cross USD 364 billion by 2035 | Roots Analysis

Published: January 2024


According to a recently published report by Roots Analysis, the rising incidence of cancer along with the growing preference for a personalized healthcare is driving the oncology precision medicine market growth.

Oncology Precision Medicine Industry Overview

The global oncology precision medicine market is anticipated to grow at a CAGR of 8.93% from 2024-2035, reaching USD 364 billion by 2035.

Oncology precision medicine, also referred to as personalized medicine in oncology, is an approach of treating cancer patients by employing genomic testing to determine the genetic characteristics of the patients’ cancerous tumors and customize the best-suited treatment options. The oncology precision medicines act by identifying the cancer-driver biomarkers expressed on the surface of the tumor cell and targeting the mutated genes in those cells. As a result, oncology precision medicines offer a highly specific therapeutic regimen with reduced impact on non-cancerous cells. Further, oncology precision medicine has demonstrated significant increase in the survival rate of cancer patients with death rates reducing by more than 30% during the period of 1991-2019. Owing to such successful therapeutic outcomes, physicians are proactively engaged in delivering precision cancer care to patient diagnosed with hard-to-treat oncological disorders. This has resulted in increased research and development efforts by precision medicine oncology companies in order to introduce novel drugs into the precision oncology market. Driven by the growing demand for targeted therapies, the oncology precision medicine market value is poised to experience noteworthy increase during the forecast period.

Browse 205+ figures and 235+ market data tables spread across 455+ pages and detailed Table of Content on “Oncology Precision Medicine Market, Till 2035 by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts” here: https: //www.rootsanalysis.com/reports/oncology-precision-medicine-market.html

Market Drivers

Several factors are propelling the growth of the oncology precision medicine market. One of the key factors driving the future of precision oncology market is the growing preference for personalized healthcare wherein treatment is prescribed based on unique genetic makeup of the patient. Further, the ability of oncology precision medicine to selectively target the genetic and molecular alterations in tumor cells and minimize the damage to normal tissues, results in reduced side effects. Additionally, owing to the exponential rise in the global cancer incidence, the demand for personalized medicine in oncology is also expected to witness a significant increase in the coming years.

Market Restraints

While the oncology precision medicine market is experiencing substantial growth, it also faces certain challenges which are hindering its growth. One of the primary restraints is the stringent regulatory requirements and guidelines of the governing bodies, such as Food and Drug Administration (FDA) in US, Health Canada and European Commission in Europe. The safety and efficacy standards on such drugs are often challenging to meet as they require rigorous clinical trials involving diverse patient population having mutated oncogenes specific to the drug being evaluated. Additionally, the high cost involved with precision cancer care limits the affordability of oncology precision medicine among financially challenged patients thereby creating a hindrance in the overall success of the oncology precision medicine market.

Growth Factors

Despite the challenges, several growth factors continue to drive the precision oncology market forward. One notable factor is the high positive response rate (>75%) of oncology precision medicine in the treatment of oncological indications. Further, stakeholders engaged in this domain are incorporating the use of companion diagnostic tests in order to identify genetic mutations as drug targets in cancer patients. Based on this, the precision medicine oncology companies are developing novel drugs having the ability to target the cancer-driver genetic abnormalities. Additionally, several large players are strategically investing their capital in acquiring small precision medicine oncology companies in order to strengthen their current pipeline of targeted drugs. Owing to the aforementioned factors, it can be anticipated that the global oncology precision medicine market will flourish remarkably in the foreseen future.

Oncology Precision Medicine Market Segments

Based on the type of cancer targeted, the market is segmented into Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others.

  • Precision medicines for blood / hematologic cancer led the oncology precision medicine market, capturing the largest revenue share of more than 25% in 2023.
  • Precision medicines for lung cancer is anticipated to show the highest growth rate of more than 10% during 2023-2035.

Based on the route of administration, the market is segmented into Oral, Intravenous and Others.

  • The precision medicines administered through intravenous route led the oncology precision medicine market, capturing the largest revenue share of more than 55% in 2023.
  • The oral route is anticipated to show the highest growth rate of close to 10% during 2023-2035.

Based on the type of molecule, the market is segmented into Small Molecules and Biologics.

  • The biologics segment led the oncology precision medicine market, capturing the largest revenue share of close to 55% in 2023.
  • The small molecules segment is anticipated to show the highest growth rate of more than 10% during 2023-2035.

Based on the drug class, the market is segmented into Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others.

  • The kinase inhibitors segment led the oncology precision medicine market, capturing the largest revenue share of more than 50% in 2023.
  • The enzyme inhibitors segment is anticipated to show the highest growth rate of around 11.43% during 2023-2035.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia, Middle East and North Africa and Latin America.

  • North America dominated the oncology precision medicine market and accounted for the largest revenue share of more than 40% in 2023.
  • In Asia, the oncology precision medicine market is anticipated to demonstrate lucrative growth during the forecast period, 2024-2035.

Key Companies Profiled

The oncology precision medicine market report also includes detailed profiles of key players (listed below) that offer oncology precision medicine:

  • AbbVie
  • Anticancer Bioscience
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Blueprint Medicines
  • Bristol Myers Squibb
  • Eli Lilly
  • Erasca
  • Genentech
  • GlaxoSmithKline
  • Hutchmed
  • IDEAYA Biosciences
  • Jiangsu Hengrui Pharmaceuticals
  • Johnson & Johnson Innovative Medicine
  • Merck
  • Novartis
  • Pfizer
  • Repare Therapeutics
  • Roche
  • Seagen
  • SpringWorks Therapeutics
  • Takeda Pharmaceutical
  • VERAXA Biotech GmbH
  • VRise Therapeutics

You Can Download Free Sample PDF Copy Of This Report at:
https://www.rootsanalysis.com/reports/oncology-precision-medicine-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Blog: https://www.rootsanalysis.com/blog/oncology-precision-medicine/

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry